Why it may matterVerify against the original reporting
The flood directly lowers 2026 revenue and EPS guidance, with quantified impacts ($7M in Q3, $15–$20M in Q4). Although insurance recoveries may offset much of the earnings impact, the lower guidance and delayed recovery raise downside risk in the near term. Similar manufacturing-disruption events historically depress stock prices until stabilization and clearer recovery timelines emerge; the negative sentiment should persist until Q3/Q4 visibility improves.
AI summary
What happened, with direct paths to the underlying reporting
Integra LifeSciences disclosed unaudited Q3 results and lowered 2026 guidance due to a July flood at its Cincinnati facility. The disruption depresses Q3 revenue by about $7 million and Q4 by $15–$20 million, reducing full-year revenue to $1.634–$1.654 billion and adjusted EPS to $2.30–$2.40. The company expects insurance recoveries to mitigate much of the earnings impact, with manufacturing activity returning to full pace by the second quarter of 2027.
Cincinnati flood hits Integra; Q3 revenue down $7M; Q4 down $15–$20M.
Full-year revenue guidance cut to $1.634–$1.654B; EPS $2.30–$2.40.
Cincinnati site to return to full manufacturing in 2Q 2027.
Insurance recoveries to offset a substantial portion of losses.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
- Integra delivered adjusted EPS of 55 cents in Q1 2024, down 25.7% YoY. - Total revenues dropped 3.2% YoY to $368.9 million, beating estimates by 1.9%. - Revenue in the Codman Sp…
